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Idiopathic hypercalciuria is a major risk factor for kidney stones, which affect 5 to 10% of the 
population and are increasing on a global scale. Potential causes for idiopathic hypercalciuria 
include increased intestinal absorption, abnormal bone resorption, and reduced reabsorption 
of calcium by the kidney (1). In steady state, the kidney tubules reabsorb approximately 98% 
of the filtrated Ca
2+
, via transcellular and paracellular pathways. The transcellular pathway is 
mediated by transporters expressed in the apical and basolateral membrane domains of cells, 
whereas the paracellular pathway depends on transepithelial electrochemical gradients and 
involves specialized proteins, the claudins (2).  
The claudins belong to a family of membrane proteins encoded by 27 genes. Their 
structure includes 4 transmembrane domains and 2 extracellular loops, with the COOH- and 
NH2-terminal domains located in the cytosol (Figure 1). The claudins form homo- and 
heteropolymers in the tight junction complexes, primarily acting as pores or barrier structures, 
defining permeability and selectivity of the paracellular space (3). Through specific 
expression profiles and interactions, the claudins play a major role in paracellular transport 
along the kidney tubule. For instance, the leaky epithelium lining the proximal tubule is 
involved in the paracellular reabsorption of water and many different solutes, largely 
determined by the expression of claudin-2 and claudin-10a (4). Isolated proximal tubules from 
claudin-2 knockout (Cldn2Y/-) mice show increased paracellular shunt resistance, indicating 
that they are “tighter” compared to those isolated from control, Cldn2Y/+ mice. Furthermore, 
the Cldn2Y/-mice are hypercalciuric, suggesting that claudin-2 plays a role in the paracellular 
reabsorption of Ca
2+
 in the proximal tubule (5). 
The role of claudin-2 in the tubular handling of Ca
2+
 and in idiopathic hypercalciuria 
and kidney stones is supported by a recent study, based on the Cldn2 mouse model and on 
genetic evidence obtained in population-based and rare family studies (6).  
In this elegant work, Curry et al. first confirmed that Cldn2Y/- mice show hypercalciuria 
without changes in glomerular filtration rate or serum calcium levels, even after a calcium-
deficient diet, and without compensatory changes in distal tubular Ca
2+
 transporters. These 
data support the existence of a defective paracellular transport of Ca
2+
 in the proximal tubule 
of Cldn2Y/- mice. Levels of parathyroid hormone (PTH) and 1,25 diOH vitamin D3, and bone 
mineral density were unchanged in Cldn2Y/- mice, suggesting that increased enteral absorption 
of calcium may contribute to the observed hypercalciuria. This hypothesis was confirmed by 
the marked attenuation of hypercalciuria when the Cldn2Y/- mice were exposed to a calcium-
deficient diet. The Cldn2Y/- mice showed a reduction in paracellular Ca2+ permeability in the 
colon, hence a reduced passive secretion of Ca
2+
, explaining the net increased intestinal 
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absorption. Importantly, aged Cldn2Y/- mice exhibited papillary nephrocalcinosis, made up of 
hydroxyapatite (calcium phosphate) with a small amount of calcium carbonate. The majority 
of deposits are not localized in a specific part of the tubules, suggesting that they were formed 
in the interstitium or by tubules that subsequently degenerated. 
To test the human relevance of these findings, the authors examined 12 single-
nucleotide polymorphisms (SNPs) in the CLDN2 locus in a population of more than 10,000 
kidney stone cases and nearly 200,000 controls (6). They found 9 SNPs (all in the non-coding 
region of CLDN2) that were significantly associated (P < 0.05) with the risk of kidney stones 
in this cohort. For 6 of these SNPs, the risk allele was strongly associated with decreased 
expression of claudin-2 in pancreatic tissue (taken as index tissue in the absence of sufficient 
kidney samples) in the Genotype-Tissue-Expression (GTEx) project. Finally, the authors 
detected a rare missense variant in CLDN2 (p.Gly161Arg) in 5 male subjects from a family of 
Iranian origin presenting with obstructive azoospermia and a history of kidney stones with 
marked hypercalciuria, compared to 2 unaffected siblings. A female carrier in the family 
exhibited mild hypercalciuria. 
 Overall, the findings of Curry et al. provide multi-level evidence suggesting a role for 
claudin-2 in idiopathic hypercalciuria and kidney stones (6). Although these findings should 
be confirmed by more direct evidence such as micropuncture studies, these results 
substantiate the role of claudin-2 in the paracellular pathway for Ca
2+
 operating in the kidney 
proximal tubule and the colon. The Cldn2Y/- mice show a combination of reduced kidney 
calcium reabsorption and increased gut absorption of calcium (due to reduced passive 
backleak in the colon), similar to many subjects with idopathic hypercalciuria (1). In turn, the 
hypercalciuria leads to papillary nephrocalcinosis in Cldn2Y/- mice, also resembling the 
intratubular plugs and interstitial plaques observed in patients with kidney stones (Figure 1). 
The increased risk of kidney stones observed in carriers of CLDN2 variants that reduce the 
expression or function of claudin-2 adds to the existing genetic evidence supporting the role 
of the paracellular pathway in Ca
2+
 handling and the risk of kidney stones. Recently, common 
variants in CLDN14 were associated with the risk of kidney stones and the specific handling 




) in the thick ascending limb (7). 
Future studies should provide additional information about the effects of the CLDN2 
variants on the structure of the tight junctions, the handling of Ca
2+
 and other solutes by 
kidneys and the gut, and the influence of diet, genetic dosage, and gender. These insights 
should also substantiate the potential therapeutic value of modulating the paracellular route of 
Ca
2+
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Figure 1. Role of claudin-2 in the paracellular pathway for calcium and the propensity 
for kidney stones. 
The epithelial cells lining the kidney proximal tubule and the colon are connected by tight 
junction (TJ) complexes delineating the apical and basolateral domains and forming a 
paracellular barrier. The claudins are cell-cell adhesion molecules that are an essential 
component of the tight junctions. The claudins typically contain 4 transmembrane domains 
and 2 extracellular loops, with the N-terminal and C-terminal region in the cytosol. The 
claudins polymerize to form tight junction strands through cis (intracellular) and trans 
(intercellular) interactions. These interactions can involve different claudin isoforms. Claudin-
2, which is represented here, interacts with the TJ protein ZO-1 through a PDZ-binding motif 
at the C-terminus (indicated by the red box). ZO-1 binds to actin and to the transcription 
factor ZONAB, which is involved in epithelial differentiation (8,9). 
Using a combination of mouse and genetic studies, Curry et al. demonstrate that claudin-2 
plays a role in the paracellular pathway for Ca
2+
 operating in the kidney proximal tubule and 
the colon. The Cldn2Y/- mice show a combination of reduced kidney calcium reabsorption and 
increased gut absorption of calcium, leading to hypercalciuria, papillary nephrocalcinosis and 
kidney stones. Carriers of CLDN2 variants reducing the expression or function of claudin-2 
also show increased risk of kidney stones. 
Adapted from (3)The Claudins: From Tight Junctions to Biological Systems. Tsukita S, 
Tanaka H, Tamura A. Trends Biochem Sci. 2019 Feb;44(2):141-152.with permission from 
Elsevier  
And  
(8) Festa BP, Chen Z, Berquez M, Debaix H, Tokonami N, Prange JA, Hoek GV, Alessio C, 
Raimondi A, Nevo N, Giles RH, Devuyst O, Luciani A. Impaired autophagy bridges 
lysosomal storage disease and epithelial dysfunction in the kidney. Nat Commun. 2018 Jan 
11;9(1):161. Under Creative Commons Attribution 4.0 International License, 
 
And  
(9) Venugopal S, Anwer S, Szászi K. Claudin-2: Roles beyond Permeability Functions. Int J 
Mol Sci. 2019 Nov 12;20(22). pii: E5655. 
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